Treatment of Severe Agitated Patients with Psychosis

Initial Approach

The American Academy of Pediatrics recommends verbal de-escalation as the first-line approach for managing acute agitation in patients with psychosis, as it is the preferred initial intervention 1
Creating a calming environment with decreased sensory stimulation and removing potential weapons from the immediate area is crucial for de-escalation 1
Removing or modifying triggers of agitation, including argumentative family members or staff, and minimizing wait times can help prevent escalation 1
Healthcare providers should take personal safety precautions, such as removing neckties and securing long hair, when interacting with agitated patients 1

The treatment guidelines suggest that a combination of an atypical antipsychotic, such as olanzapine 10 mg IM or oral risperidone 2 mg, plus lorazepam 2 mg, provides rapid tranquilization with fewer extrapyramidal side effects than haloperidol-based regimens 1, 2, 3
For cooperative patients, oral olanzapine 2.5-5 mg plus lorazepam 2 mg is the preferred regimen, offering rapid onset with minimal cardiac effects 3
Alternative regimens, such as oral risperidone 2 mg plus lorazepam 2 mg, produce similar improvement to haloperidol combinations but with significantly fewer extrapyramidal symptoms 3

If substance use is suspected or confirmed, lorazepam 2-4 mg IM/IV should be the first-line treatment, as it addresses potential withdrawal syndromes and avoids exacerbating anticholinergic or sympathomimetic toxicity 2
Benzodiazepines are as effective as conventional antipsychotics for undifferentiated agitation and are therapeutic if agitation stems from alcohol or benzodiazepine withdrawal 2
Antipsychotic monotherapy should be avoided if anticholinergic or sympathomimetic intoxication is suspected, as these agents can worsen agitation 2

Vital signs and sedation level should be monitored every 5-15 minutes during the first hour after medication administration 2
Baseline ECG should be obtained if using droperidol or if cardiac risk factors are present 2, 3
Olanzapine has the least QTc prolongation (2 ms) compared to haloperidol (7 ms), making it safer for patients with cardiac disease 3

Haloperidol monotherapy should be avoided due to high rates of acute dystonia and extrapyramidal symptoms 3
Thioridazine should never be used due to severe QTc prolongation (25-30 ms) 3
Droperidol requires caution due to the FDA black box warning regarding dysrhythmias 3

Oral formulation should be started within 12-24 hours after the last parenteral dose, and the same atypical antipsychotic used for acute management should be continued to maintain therapeutic consistency 3
For patients stabilized on olanzapine, the maintenance dose is 2.5 mg daily at bedtime, with a maximum of 10 mg/day in divided doses 3
For risperidone, the target maintenance dose is 2 mg/day, avoiding doses ≥6 mg/day due to increased extrapyramidal symptoms 3